Comprehensive Aerodynamic and Physicochemical Stability Evaluations of Nanocrystal-Based Dry Powder Inhalers: The Role of Mannitol and Leucine in Enhancing Performance. [PDF]
Banat H +4 more
europepmc +1 more source
Demographic and Asthma-Related Characteristics of Asthmatics Using Pressurized Metered Dose Inhalers and Dry Powder Inhalers. [PDF]
Aksu K +10 more
europepmc +1 more source
Peak inspiratory flow in children and adolescents with asthma using dry powder inhalers: a cross-sectional study. [PDF]
Silva CPD +4 more
europepmc +1 more source
Optimisation of dry powder inhalation
Inhalatiegeneesmiddelen worden gegeven in doseringen variërend van enkele microgrammen tot enkele honderden milligrammen. Een gemiddelde poederdosis van 400 microgram (µg) heeft de grootte van een enkel suikerkristal. Om hieruit deeltjes van 0.001 tot 0.005 mm te krijgen moet het kristal tot globaal 2 tot 8 miljoen kleinere deeltjes worden vermalen ...
openaire +1 more source
Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD. [PDF]
Jõgi R +6 more
europepmc +1 more source
Dry powder inhalation of antibiotics
In the thesis of Marcel Hoppentocht the feasibility to treat bacterial infections effectively with inhaled dry powder antibiotics is explored. Most antibiotics are currently administered pulmonary by wet nebulisation or via the parenteral route and both methods have numerous disadvantages. For instance, needle fear and the need for ‘cold chain storage’
openaire +1 more source
Comprehensive In Vitro and In Silico Aerodynamic Analysis of High-Dose Ibuprofen- and Mannitol-Containing Dry Powder Inhalers for the Treatment of Cystic Fibrosis. [PDF]
Party P +3 more
europepmc +1 more source
Comparisons between In-Check DIAL® and PF810® in evaluation and training inspiratory capacity for using dry powder inhalers. [PDF]
Wu Y, Li L, Gong Y, Li X, Ye X, Zhang J.
europepmc +1 more source
Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers. [PDF]
Acosta MF +5 more
europepmc +1 more source
Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler (R) [PDF]
BENGTSSON, T +3 more
core +1 more source

